Canadian pharmaceutical company Apotex Health Corp (TSX:APTX) announced on Monday the US launch of Axitinib Tablets, 1 mg and 5 mg, the first generic version of Pfizer's INLYTA, a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Renal cell carcinoma is the most common type of kidney cancer in adults and accounts for approximately 90% of kidney cancer diagnoses. Axitinab Tablets provide an additional FDA-approved treatment option for appropriate patients with advanced RCC following failure of one prior systemic therapy.
Axitinib Tablets are supplied as 1 mg tablets in bottles of 180 (NDC 60505-4427-8) and 5 mg tablets in bottles of 60 (NDC 60505-4428-6).
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Akeso publishes ivonescimab Phase II study results in Nature Medicine
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma